Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Selective MAO-B inhibitor

Selegiline hydrochloride

Brand names: Eldepryl

Selegiline hydrochloride is a monoamine oxidase-B inhibitor used as an adjunct in Parkinson's disease, often with levodopa, to prolong dopaminergic effect.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

At usual doses it selectively and irreversibly inhibits monoamine oxidase type B, reducing the breakdown of dopamine in the brain.

Prescribing in practice

  • Combination with serotonergic agents such as SSRIs, SNRIs, tricyclics or pethidine risks serotonin toxicity, so these combinations should be avoided and washout periods observed.
  • Adding selegiline to levodopa may potentiate dopaminergic adverse effects such as dyskinesia, postural hypotension and confusion, which may require levodopa dose reduction.
  • MAO-B selectivity can diminish at higher doses, raising the theoretical risk of tyramine-related hypertensive reactions.

Monitoring

Monitor blood pressure, motor response and for confusion or hallucinations, especially during initiation and dose changes.

Counselling the patient

  • Report dizziness on standing, vivid dreams, confusion or involuntary movements.
  • Tell any prescriber you take selegiline before starting antidepressants or strong painkillers.
  • Do not stop suddenly without advice.

Evidence & guidelines

MAO-B inhibitors are established adjuncts in Parkinson's disease management, supported by NICE guidance on motor symptom control.

Reference: NICE NG71; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways